{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:29:53Z","timestamp":1783686593422,"version":"3.55.0"},"reference-count":34,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,1,23]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with atopic dermatitis (AD), also known as eczema, may be at an increased risk for malignancies compared with patients without AD; however, incidence rates (IRs) of malignancies in patients with moderate to severe AD are largely unknown. The objective of this study was to evaluate and compare IRs of malignancies in adults with moderate to severe AD (aged \u226518 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study using data from a Kaiser Permanente Northern California (KPNC) cohort. AD severity classification was adjudicated with medical chart review. Covariates and stratification variables included age, sex and smoking status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Data were obtained from the KPNC healthcare delivery system in northern California, USA. Cases of AD were defined by outpatient dermatologist-rendered codes and prescriptions of topical therapy or phototherapy (moderate) or systemic treatment (severe).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>KPNC health plan members with moderate or severe AD (2007\u20132018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Malignancy IRs and 95% CIs per 1000 person-years were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>7050 KPNC health plan members with moderate and severe AD met eligibility criteria for inclusion. IRs (95% CI) were highest for non-melanoma skin cancer (NMSC) in patients with moderate and severe AD (4.6 (95% CI 3.9 to 5.5) and 5.9 (95% CI 3.8 to 9.2), respectively) and breast cancer (2.2 (95% CI 1.6 to 3.0) and 0.5 (95% CI 0.1 to 3.9), respectively). Except for breast cancer, which was only evaluated in women, malignancies were higher (with non-overlapping CIs) in patients with moderate and moderate to severe AD in men versus women for basal cell carcinoma and NMSC and in former versus never smokers for NMSC and squamous cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study estimated IRs of malignancies in patients with moderate and severe AD and provides valuable information for dermatology clinicians and ongoing clinical trials in these populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-071172","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T08:03:29Z","timestamp":1678435409000},"page":"e071172","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Rates of malignancies among patients with moderate to severe atopic dermatitis: a retrospective cohort study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1768-0412","authenticated-orcid":false,"given":"Monique M","family":"Hedderson","sequence":"first","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam M","family":"Asgari","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles P","family":"Quesenberry","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Oakland, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Geier","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina R","family":"Lemeshow","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"2025121407012460000_13.3.e071172.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025121407012460000_13.3.e071172.2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdin.2020.10.002","article-title":"The global, regional, and national burden of atopic dermatitis in 195 countries and territories: an ecological study from the global burden of disease study 2017","volume":"2","author":"Urban","year":"2021","journal-title":"JAAD Int"},{"key":"2025121407012460000_13.3.e071172.3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/bjd.19580","article-title":"The global burden of atopic dermatitis: lessons from the global burden of disease study 1990-2017","volume":"184","author":"Laughter","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025121407012460000_13.3.e071172.4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025121407012460000_13.3.e071172.5","doi-asserted-by":"publisher","DOI":"10.1159\/000370220"},{"key":"2025121407012460000_13.3.e071172.6","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2025121407012460000_13.3.e071172.7","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.446"},{"key":"2025121407012460000_13.3.e071172.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra074081"},{"key":"2025121407012460000_13.3.e071172.9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","article-title":"Atopic dermatitis: pathophysiology","volume":"1027","author":"David Boothe","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"2025121407012460000_13.3.e071172.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.06.025"},{"key":"2025121407012460000_13.3.e071172.11","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.9.1123"},{"key":"2025121407012460000_13.3.e071172.12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.0022-202X.2005.23839.x","article-title":"The risk of cancer among patients previously hospitalized for atopic dermatitis","volume":"125","author":"Olesen","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2025121407012460000_13.3.e071172.13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: beyond allergic disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025121407012460000_13.3.e071172.14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/jamadermatol.2019.3786","article-title":"Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"156","author":"Wang","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025121407012460000_13.3.e071172.15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2340\/00015555-2703","article-title":"Prevalence of cancer in adult patients with atopic dermatitis: a nationwide study","volume":"97","author":"Ruff","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2025121407012460000_13.3.e071172.16","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","article-title":"Association between atopic eczema and cancer in England and Denmark","volume":"156","author":"Mansfield","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025121407012460000_13.3.e071172.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277469","article-title":"Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: a retrospective cohort study","volume":"17","author":"Hedderson","year":"2022","journal-title":"PLoS One"},{"key":"2025121407012460000_13.3.e071172.18","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/15-225"},{"key":"2025121407012460000_13.3.e071172.19","unstructured":"Surveillance epidemiology and end results (SEER) program. SEER*stat databases: november 2019 submission. Bethesda, MD: National Cancer Insitute; 2019. Available: https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2019\/#records [Accessed 7 Jan 2021]."},{"key":"2025121407012460000_13.3.e071172.20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","article-title":"Global, regional, and National cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study","volume":"5","author":"Fitzmaurice","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025121407012460000_13.3.e071172.21","unstructured":"National Cancer Insitute . SEER Cancer Stat Facts. Available: https:\/\/seer.cancer.gov\/statfacts\/ [Accessed 10 Jan 2022]."},{"key":"2025121407012460000_13.3.e071172.22","unstructured":"National Cancer Insitute . State cancer profiles. Available: https:\/\/statecancerprofiles.cancer.gov\/ [Accessed 10 Jan 2022]."},{"key":"2025121407012460000_13.3.e071172.23","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2010.e13","article-title":"Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs","volume":"2","author":"Lerche","year":"2010","journal-title":"Dermatol Reports"},{"key":"2025121407012460000_13.3.e071172.24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamadermatol.2018.4216","article-title":"Association between health maintenance practices and skin cancer risk as a possible source of detection bias","volume":"155","author":"Drucker","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025121407012460000_13.3.e071172.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.12.668"},{"key":"2025121407012460000_13.3.e071172.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.001"},{"key":"2025121407012460000_13.3.e071172.27","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.133"},{"key":"2025121407012460000_13.3.e071172.28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025121407012460000_13.3.e071172.29","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/cea.12178","article-title":"Epidemiological associations of allergy, IgE and cancer","volume":"43","author":"Josephs","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"2025121407012460000_13.3.e071172.30","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaad.2015.02.1116","article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis","volume":"72","author":"Legendre","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025121407012460000_13.3.e071172.31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13671-017-0168-7","article-title":"Comorbidities of atopic dermatitis: beyond rhinitis and asthma","volume":"6","author":"Andersen","year":"2017","journal-title":"Curr Dermatol Rep"},{"key":"2025121407012460000_13.3.e071172.32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: should we be paying more attention?","volume":"16","author":"Loft","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121407012460000_13.3.e071172.33","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2016.10.006","article-title":"Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population","volume":"76","author":"Asgari","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2025121407012460000_13.3.e071172.34","doi-asserted-by":"crossref","unstructured":"Gordon NP . Similarity of the adult Kaiser Permanente membership in Northern California to the insured and general population in Northern California: statistics from the 2011 California Health Interview Survey. Oakland, CA: Kaiser Permanente Division of Research; 2015. Available: https:\/\/divisionofresearch.kaiserpermanente.org\/projects\/memberhealthsurvey\/SiteCollectionDocuments\/chis_non_kp_2011.pdf [Accessed 11 Apr 2021].","DOI":"10.7812\/TPP\/15-225"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-071172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:01:34Z","timestamp":1765724494000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-071172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,10]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/bmjopen-2022-071172"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-071172","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}